ClinicalTrials.Veeva

Menu

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Semaglutide

Study type

Observational

Funder types

Industry

Identifiers

NCT06351748
U1111-1296-3151 (Other Identifier)
NN9535-7877

Details and patient eligibility

About

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Enrollment

34,238 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female participants aged greater than or equal to (≥) 18 years on index date
  • Participants with diagnosis of T2DM prior to or on index date
  • Participants with initiation of semaglutide OW for the first time within the identification period

Exclusion criteria

  • Participants with diagnosis of type 1 diabetes prior to or on index date
  • Participants who were pregnant within 36 months prior to or on index date
  • Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records

Trial design

34,238 participants in 1 patient group

Participants with T2DM
Description:
Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023.
Treatment:
Drug: Semaglutide

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems